From GlobeNewswire:

Ampligen, a potential therapeutic for Post-COVID fatigue, has shown preliminary evidence of reducing fatigue symptoms in a Phase 2 clinical trial. Subjects receiving Ampligen showed lower fatigue levels compared to the placebo group. Primary and secondary outcome measures reached or approached statistical significance during several timepoints in the treatment phase. Furthermore, Ampligen was generally well tolerated, with no severe adverse events. These positive results validate AIM ImmunoTech’s confidence in the potential effectiveness of Ampligen for Post-COVID fatigue.

In the Phase 2 study, the Ampligen group experienced lower levels of fatigue at multiple time points compared to the placebo group. Safety analysis confirmed the general tolerability of Ampligen in the treatment of Post-COVID conditions. Eighty subjects, half of which were given Ampligen, completed the treatment, and both groups had similar demographics and baseline characteristics. These promising findings support AIM’s belief in Ampligen’s potential for treating Post-COVID fatigue.

These findings provide encouraging preliminary results on the use of Ampligen to relieve fatigue symptoms in subjects with Post-COVID conditions. The significant impact of Ampligen on reducing fatigue supports future trials for its development. Safety results also confirm the tolerability of Ampligen. This study solidifies AIM ImmunoTech’s belief in the potential of Ampligen for addressing Post-COVID fatigue.



Read more: AIM ImmunoTech Reports Positive Topline Results from Phase